EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Invex Therapeutics's Enterprise Value is A$0.16 Mil.
Invex Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-5.27 Mil. Therefore, Invex Therapeutics's EV-to-FCF for today is -0.03.
The historical rank and industry rank for Invex Therapeutics's EV-to-FCF or its related term are showing as below:
ASX:IXC'
s EV-to-FCF Range Over the Past 10 Years
Min: -13.41 Med: 0 Max: 2.45
Current: -0.03
During the past 4 years, the highest EV-to-FCF of Invex Therapeutics was 2.45. The lowest was -13.41. And the median was 0.00.
ASX:IXC's EV-to-FCF is ranked better than 92.74% of 372
companies
in the Biotechnology industry
Industry Median: 8.36
vs ASX:IXC: -0.03
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Invex Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Invex Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Invex Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invex Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Invex Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Invex Therapeutics's EV-to-FCF falls into.
Invex Therapeutics's current Enterprise Value is A$0.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invex Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-5.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Invex Therapeutics's PE Ratio for today is calculated as:
Invex Therapeutics's share price for today is A$0.084.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invex Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Invex Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Invex Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:IXC has been successfully added to your 